U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H15ClNO4.Na
Molecular Weight 331.727
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROMAZARIT SODIUM

SMILES

[Na+].CC1=C(COC(C)(C)C([O-])=O)OC(=N1)C2=CC=C(Cl)C=C2

InChI

InChIKey=IXEKPMAYILRTFK-UHFFFAOYSA-M
InChI=1S/C15H16ClNO4.Na/c1-9-12(8-20-15(2,3)14(18)19)21-13(17-9)10-4-6-11(16)7-5-10;/h4-7H,8H2,1-3H3,(H,18,19);/q;+1/p-1

HIDE SMILES / InChI
Molecular Formula C15H15ClNO4
Molecular Weight 308.737
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Romazarit, (Ro 31-3948, 7), 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methylpropionic acid is a substituted heterocyclic alkoxypropionic acid. Romazarit was considered to be a potential disease-modifying antirheumatic drug. Romazarit was withdrawn due to its toxicity profile.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
144 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2088768
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROMAZARIT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
958 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2088768
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROMAZARIT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Highest studied dose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2088768
healthy, ,ADULT
Health Status: healthy
Age Group: ,ADULT
Sex: M
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/2088768
Sources:
https://pubmed.ncbi.nlm.nih.gov/2088768
Sourcing

Sourcing

Vendor/AggregatorIDURL
Alfa Chemistry
36848
http://www.alfa-chemistry.com/search.aspx?q=36848
Alfa Chemistry
ACM109543762
http://www.alfa-chemistry.com/search.aspx?q=ACM109543762
Compound Cloud
71321
MuseChem
M008133
https://www.musechem.com/product/M008133.html
Tetrahedron
TS60829
http://www.thsci.com/search.do?q=TS60829
PubMed

PubMed

TitleDatePubMed
Synthesis of 4-benzyl-1,3-thiazole derivatives as potential anti-inflammatory agents: an analogue-based drug design approach.
2009-06
Tetra substituted thiophenes as anti-inflammatory agents: exploitation of analogue-based drug design.
2005-12-15
Population pharmacodynamics of romazarit.
1995-03
A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis.
1992-03
Romazarit: a potential disease-modifying antirheumatic drug.
1991-02
Pharmacokinetics and tolerance of romazarit after oral administration of ascending single doses to healthy human volunteers.
1990-10-01
Biologic properties of romazarit (Ro 31-3948), a potential disease-modifying antirheumatic drug.
1990-03
Patents

Patents

JP2011524416A
146

Sample Use Guides

In Vivo Use Guide
patients with rheumatoid arthritis: 200 mg or 450 mg every 12 h for up to 24 weeks, 100 mg t.i.d., 350 mg b.i.d., or 350 mg t.i.d., for 6 days.
Route of Administration: Oral
In Vitro Use Guide
In vitro romazarit was an extremely weak inhibitor of prostaglandin synthetase activity in both sheep seminal vesicle (IC50 6500 microM) and rat renal medulla (IC50 greater than 300 microM) cell-free preparations.
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:05:15 GMT 2025
Edited
by admin
on Mon Mar 31 23:05:15 GMT 2025
Record UNII
TK7BS24A7A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROMAZARIT SODIUM
Common Name English
RO-31-3948/002
Preferred Name English
SODIUM 2-((2-(4-CHLOROPHENYL)-4-METHYL-1,3-OXAZOL-5-YL)METHOXY)-2-METHYLPROPANOATE
Systematic Name English
PROPANOIC ACID, 2-((2-(4-CHLOROPHENYL)-4-METHYL-5-OXAZOLYL)METHOXY)-2-METHYL-, SODIUM SALT
Common Name English
Code System Code Type Description
CAS
109544-09-4
Created by admin on Mon Mar 31 23:05:15 GMT 2025 , Edited by admin on Mon Mar 31 23:05:15 GMT 2025
PRIMARY
FDA UNII
TK7BS24A7A
Created by admin on Mon Mar 31 23:05:15 GMT 2025 , Edited by admin on Mon Mar 31 23:05:15 GMT 2025
PRIMARY
EPA CompTox
DTXSID30911236
Created by admin on Mon Mar 31 23:05:15 GMT 2025 , Edited by admin on Mon Mar 31 23:05:15 GMT 2025
PRIMARY
PUBCHEM
23663984
Created by admin on Mon Mar 31 23:05:15 GMT 2025 , Edited by admin on Mon Mar 31 23:05:15 GMT 2025
PRIMARY
Related Record Type Details
Structure of ROMAZARIT
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ROMAZARIT
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966